Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Over $4 million dollar volume already today, looks like the brutal dilution falling knife thing is done
https://ih.advfn.com/stock-market/USOTC/sysorex-qb-SYSX/stock-price
SYSX $$$
Hard telling, I'm back in lol
SYSX $$$
Pretty active on Twitter including replies
https://twitter.com/cordiakitchens
CORG $$$
Looking great. Still loading this range https://www.fox13news.com/video/1061977
GRLT $$$
Sweet quarterly out
https://www.otcmarkets.com/stock/HIRU/disclosure
HIRU $$$
Yeah pretty strange seeing so many huge buys from Frank and the sp this much lower now. Not a good look atm
NIHK $$$
Is it? I'd love to see an order screenshot tia
Have a great weekend everybody. See you in June lol
DBOOMM $$$
I wonder who can still buy at this point, and where the limited volume is coming from and how. Been months since Schwab put the kibosh on buying, and jmho I doubt Canadians have been able to trade it for a while too
DBOOMM $$$
Been seeing their ads and the "baby soft braker" guy made me think this is IGEN related
https://www.usaa.com/inet/wc/insurance-safe-driving-landing-mkt
IGEN $$$
Not a chance. Maybe sometime in the future they'll start filing again
https://www.otcmarkets.com/stock/FZRO/disclosure
Shorts are nervous with good reason. If and when the CE drops, this should rocket. Glad to have plenty of shares
Zero shares traded today and yet still 30 posts today alone, how in the hell does DBMM still have this much interest day in and day out since the GURANTEED revocation that was promised years and YEARS ago??? So very interesting!
Vivos Inc Implements Multiple Patient IsoPet® Therapy Day
Richland WA, April 21, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce a combined IsoPet® therapy schedule into one treatment day, allowing for one production run to provide multiple Isopet® therapies that are done in any one of our current three regional clinics at Vista Veterinary Hospital in Washington, the University of Missouri and John Hopkins University in Maryland. As the number of patients increases additional days will be scheduled.
This schedule structure combines the production of the IsoPet® for all the therapies into a single run, significantly reducing our per treatment production cost and reducing shipping costs by Fed Ex when multiple treatments are scheduled at a single clinic.
As a first demonstration of this policy change John Hopkins University VCTN, Veterinary Clinical Trials Network, treated two patients this past week, a domestic short-haired and a long-haired cat from a single production run. Both animals had previously been treated via other therapies. One cat even had an amputation with a tumor reoccurring. The Isopet® treatments went smoothly from our single production run delivered via overnight delivery directly to the clinic.
In closing Dr. Korenko stated, “As the number of patients increases, we will continue to capitalize on ways to reduce cost and increase profitability. We are committed to offering a treatment option that offers significant advantages relative to other therapy options while being cognizant of the price to the pet parent.”
About Vivos Inc. (OTCQB: RDGL)
Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
The IsoPet® Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet® to University animal hospitals and private veterinary clinics.
IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
MKorenko@RadioGel.com
https://www.globenewswire.com/news-release/2022/04/21/2426650/0/en/Vivos-Inc-Implements-Multiple-Patient-IsoPet-Therapy-Day.html
RDGL $$$
Artizen Winner of the 2022 Dockside Cannabis Cup!
SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced that ArtizenTM is the winner of the esteemed Washington State 2022 Dockside Cannabis Cup.
Recognized as the 9th bestselling independent cannabis flower brand by MJ Business Magazine, Artizen further strengthened its market position by winning this year’s Dockside Cannabis Cup with its Dutchberry strain.
“Our independent cultivators do amazing work daily, growing premium cannabis flower at scale. It is great to see their work recognized by one of the state’s premier retailers and a competition that included some of the best brands and products competing against each other!” says CEO German Burtscher.
With over $17 million in sales annually, Artizen branded cannabis products have established themselves as market leaders in various categories. As the brand is about to be offered in various recreational states, this is just one more award confirming its quality and market acceptance.
Pervasip Corporation
Pervasip Corp., a developer of companies and technologies in high value emerging markets, owns Artizen Corporation and its subsidiary, Zen Asset Management LLC, a diversified asset management company founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM’s existing clients operate four licensed cannabis cultivation and one processing facility in Washington. Most of the biomass produced by these independent cultivators has been sold historically under the Artizen™ brand, including all-time top selling products in flower in Washington state. Additional information on Artizen-branded products is available online at www.artizencannabis.com. Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin. Additional information on KRTL is available online at www.krtlbiotech.com. Additional information on Pervasip can be found at www.pervasip.net.
https://www.globenewswire.com/news-release/2022/04/21/2426580/0/en/Artizen-Winner-of-the-2022-Dockside-Cannabis-Cup.html
PVSP $$$
Thanks for that Mr Zen
Hypothetically of course. But it's easier to talk about specific examples though, isn't it? That's why I'm curious which post(s) you feel is clearly inside info, and if you could please share an example? Thanks in advance :)
Thanks for the response!
Of course one can not "know" for certain. But when multiple specific non-public information is regularly referenced as fact, it certainly leads to suspicion.
For example, specific details from a legal case with the SEC, that really could only come from someone directly involved. i.e. The info isn't in any of the court filings.
Aren't there special rules regarding brokers or insiders pumping non-CE stocks?
Saw that today. Been adding this range too glta
Currently in development, #LilBuddy™ is the compact, light load version of $RGGI's flagship #PullBuddy™.
— ResgreenGroup (@ResGreenGroup) April 20, 2022
A signature feature is the hybrid navigation option that can switch between natural guidance and magnetic tape guidance.#Resgreengroup #LilBuddy™ #AMR pic.twitter.com/Ta0HoQ7L5A
How do you know the poster(s) is employed by the company? Also, any example of non-public info they're disclosing?
Does anyone know the legality of company employees posting on stock boards without identifying themselves as such? How about if they keep accidentally dropping non-public information?
A little surprised seeing $90k dollar volume yesterday and so far just $340 bucks today
https://ih.advfn.com/stock-market/USOTC/herborium-pk-HBRM/stock-price
HBRM $$$
Looking really good. Big weeks coming
IGEN $$$
William A. Hartman, Halberd's Chairman, President & CEO added, "This latest testing proves that our technology is just as capable of eradicating bacteria molecules that are many times larger than the neurodegenerative linked proteins and cytokines which Halberd has reported on in earlier press releases.
"Many people are confused by Halberd's numerous announcements regarding its successes in eliminating various target disease antigens. Contrary to popular belief, we are not indiscriminately jumping from disease to disease. All of our work revolves around verifying that our underlying patented extracorporeal treatment technology is effective against a broad range of disease antigens. We are proving that the process can be used to successfully eliminate an extensive list of disease antigens, in a fraction of the time, and without dangerous drug-induced side-effects often associated with conventional drug treatments."
https://finance.yahoo.com/news/halberd-eliminates-e-coli-20-120000132.html
HALB $$$
Great post Stervc, thank you. I agree many are sleeping on BOXS
BOXS $$$
Yes USAA may have been in the mix originally but we haven't heard mentions of them in a while. Neil says USAA approached him in his first sentence of this interview
Good looking update. I'll be adding more down here. Love to see a nice run
https://www.prnewswire.com/news-releases/upstryve-inc-formerly-probility-media-corp-announces-third-quarter-financial-results-301526380.html
PBYA $$$
Looks like 5 form 3s today for 38 million common shares
https://www.otcmarkets.com/stock/SIGN/disclosure
SIGN $$$
On April 3, 2022, IGEN Networks Corp. (the “Company” or “IGEN”) entered into an equity financing agreement (the “EFA”), a registration rights agreement (the “RRA”) and a promissory note (the “Note”) with Jefferson Street Capital, LLC (“Jefferson Street”) (the “Jefferson Street Transaction”). The EFA allows Jefferson Street to invest up to five million and no/100 dollars ($5,000,000.00) into IGEN Common Stock, par value $0.001, over a period not to exceed thirty-six (36) months. The purchase price for the Common Stock acquired by Jefferson Street will be eighty-eight percent (88%) of the VWAP for IGEN shares during the ten (10) days preceding each put notice delivered by IGEN to Jefferson Street. Jefferson Street may not hold more than 4.99% of IGEN stock at any time. As additional compensation to Jefferson Street, IGEN will issue twelve million five hundred thousand (12,500,000) shares of its Common Stock to Jefferson Street capital as commitment shares (the “Commitment Shares”).
Under the terms and subject to the conditions of the EFA the Company has the right, but not the obligation, to sell to Jefferson Street, and Jefferson Street is obligated to purchase up to $5.0 million of the Company’s Common Stock. Such sales of Common Stock by the Company, if any, will be subject to certain limitations set forth in the EFA, and may occur from time to time, at the Company’s sole discretion, over the 36-month period commencing on the date that the conditions to Jefferson Street’s purchase obligation set forth in the EFA are satisfied, including that a registration statement is filed covering the resale by Jefferson Street of shares of Common Stock that have been and may be issued to Jefferson Street under the EFA, which the Company has agreed to use its best efforts to file a registration statement with the Securities and Exchange Commission (the “SEC”), within thirty (30) days, pursuant to the RRA, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the “Commencement Date”).
The Company will control the timing and amount of any sales of Common Stock to Jefferson Street pursuant to the EFA. Jefferson Street has no right to require the Company to sell any shares of Common Stock to Jefferson Street, but Jefferson Street is obligated to make purchases as the Company directs, subject to certain conditions.
Actual sales of shares of Common Stock to Jefferson Street will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Company’s Common Stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the EFA to the Company will depend on the frequency and prices at which the Company sells shares of its stock to Jefferson Street. The Company expects that any proceeds received by the Company from such sales to Jefferson Street will be used for working capital and general corporate purposes.
The EFA prohibits the Company from directing Jefferson Street to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock then beneficially owned by Jefferson Street (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in Jefferson Street beneficially owning more than 4.99% of the outstanding shares of Common Stock.
There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the EFA or RRA.
As consideration for Jefferson Street’s irrevocable commitment to purchase shares of the Company’s Common Stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, the Company agreed to issue the Commitment Shares to Jefferson Street.
The EFA and RRA contain customary representations, warranties, conditions and indemnification obligations of the parties.
The Company also issued the Note to Jefferson Street. The Note is non-convertible and bears interest at a rate of six percent (6%) per annum, calculated on the basis of a 365 day year, and is due, in full, on or before October 3, 2022. There are no periodic payments required under the Note and the Company may pre-pay any amounts owed, in whole or part, at any time without penalty or premium for early payment. Failure to pay the Note when due will result in a default interest rate of eighteen percent (18%) being imposed upon the amounts due, plus costs and fees associated with collection of the Note.
The foregoing descriptions of the EFA, RRA and Note are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1, 10.2 and 10.3, respectively, and each of which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.
This current report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Item 1.02 Termination of a Material Definitive Agreement.
The Equity Purchase Agreement and Registration Rights Agreement entered into by and between the Company and Crown Bridge Partners, LLC on July 7, 2020, was terminated on April 9, 2022 pursuant to Section 10.5 of the Equity Purchase Agreement.
Item 3.02. Unregistered Sales of Equity Securities.
The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02.
In the EFA, Jefferson Street represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)). The securities referred to in this current report on Form 8-K, including the Commitment Shares, are being issued and sold by the Company to Jefferson Street in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D thereunder.
Item 7.01 Regulation FD Disclosure.
The information contained above in Item 1.01 is hereby incorporated by reference into this Item 7.01. On April 14, 2022 the Company issued a press release announcing the entry into the Jefferson Street Transaction. A copy of the Press Release is attached to this Form 8-K as an Exhibit.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1393540/000164033422000791/igen_8k.htm
IGEN $$$
The drawing and selling of shares will be at the sole discretion of IGEN's Officers and Board of Directors.
For what it's worth
IGEN $$$
IGEN Secures $5M Equity-Line Financing to support Product Brand Growth and Strategic Initiatives
LAKE ELSINORE, Calif., April 14, 2022 /PRNewswire/ -- IGEN Networks Corporation (OTC: IGEN, CSE: IGN), is pleased to announce agreements for $5,000,000 in Equity-Line Financing with Jefferson Street Capital LLC (JSC), a New Jersey limited liability company. Over the course of the next three years, after an effective registration of common shares, Jefferson Street Capital LLC, will invest up to $5,000,000 to fund IGEN's strategic initiatives and product brand growth for both the consumer and commercial markets. The Equity-Line was structured with favorable terms for IGEN and in close alignment with IGEN shareholder objectives that enable JSC to hold up to 4.99% of IGEN outstanding shares throughout the term of the agreements. The drawing and selling of shares will be at the sole discretion of IGEN's Officers and Board of Directors.
CEO Neil G. Chan stated, "With this new Equity-Line we are well capitalized to fund and support all five product brands offered to consumer and commercial markets:
FamilyShield – first direct-to-consumer brand to protect families and their young drivers - available for purchase on Amazon.com
Nimbo Tracking – marketed to franchise and pre-owned automotive dealerships across 50 States for Lot Management of vehicle inventory along with the offering of vehicle theft protection and FamilyShield services to automotive consumers and their families
CUTrak – a product brand created specifically to mitigate lending risk for financial institutions and credit unions along with the additional offering of FamilyShield services to members and their families
Medallion GPS – a fleet management platform designed for ease-of-use at significantly lower costs for management of Light-Duty commercial and passenger vehicles
Medallion GPS PRO – the next generation fleet management platform designed for Medium-to-Heavy Duty commercial vehicles that demand real-time 5G video performance and fleet management capabilities
In addition to supporting product brand growth opportunities, the Equity-Line will provide the necessary resources for enforcement of IGEN Intellectual Properties, the continued development of Artificial Intelligence (AI) based algorithms for improving driver safety and fleet productivity, and finally through the inherent structure of the Equity-Line, IGEN will continue to increase its stockholder equity in preparation for up-listing opportunities for both the Canadian and US securities markets".
About IGEN Networks Corporation
IGEN Networks Corporation creates software services for the consumer automotive and commercial asset management industries enabling their customers to better manage their assets and protect their drivers. IGEN is a fully reporting company in both Canada and the United States. It is publicly traded on the OTC Markets under the symbol IGEN, and listed on the CSE under the symbol IGN. For more information, please visit: www.igennetworks.net
https://www.prnewswire.com/news-releases/igen-secures-5m-equity-line-financing-to-support-product-brand-growth-and-strategic-initiatives-301526258.html
IGEN $$$
Somebody slapped 33,750,000
https://ih.advfn.com/stock-market/USOTC/herborium-pk-HBRM/trades
HBRM $$$
Really hoping it does not go through as Twitter is the pinnacle of social media, sorry Facebook, and that's why it's so important for Elon and TFG to have control there
Some great posts on the topic like this one:
Instead of buying Twitter for 43 Billion, Elon should buy Truth Social for 43 Bucks and leave us alone.
— Davram (@davramdavram) April 14, 2022
Good to see that Pink Current: https://www.otcmarkets.com/stock/HBRM/security
HBRM $$$